secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0001193125-26-192362
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus cuts workforce 13%; expects $8M restructuring charge, $15M annualized savings
--------------------------------------------------------------------------------

- Reduces workforce ~13% as part of operational efficiency plan; impacted employees receive severance and benefits.
- Expects total restructuring charges of ~$8M, primarily severance, recognized in H1 2026; plan substantially complete by Q3 2026.
- Reaffirms FY 2026 AUCATZYL net product revenue guidance of $120M-$135M, up from $74M in 2025.
- Expects ~$15M annualized cost savings beginning in 2027; aims for positive gross margin in 2026.
- Clinical programs on track: CATULUS (pediatric ALL), LUMINA (lupus nephritis), BOBCAT (MS).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000119312526192362/0001193125-26-192362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000119312526192362/d113906d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-192362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer